Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4

Clinical Cancer Research

Volumn 9, Issue 10 II, 2003, Pages

  Solomon, Alan ^a,b   Weiss, Deborah T ^a   Wall, Jonathan S ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CHIMERIC ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 11 1F4; REAGENT; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; DNA TRANSFECTION; FATALITY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

AMYLOID; ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLONING, MOLECULAR; COS CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPITOPES; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TRANSFECTION; TRANSPLANTATION;

EID: 0141791455     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Solomon, A., and Weiss, D. T. Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). Amyloid. Int. J. Exp. Clin. Investig., 2: 269-279, 1995.
2. Kyle, R. A., and Gertz, M. A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol., 32: 45-59, 1995.
3. Dhodapkar, M. V., Merlini, G., and Solomon, A. Biology and therapy of immunoglobulin deposition diseases. Hematol. Oncol. Clin. N. Am., 11: 89-110, 1997.
4. Falk, R. H., Comenzo, R. L., and Skinner, M. The systemic amyloidoses. N. Engl. J. Med., 337: 898-909, 1997.
5. Gertz, M. A., and Kyle, R. A. Amyloidosis: prognosis and treatment. Semin. Arthritis Rheum., 24: 124-138, 1994.
6. Skinner, M., Anderson, J., Simms, R., Falk, R., Wang, M., Libbey, C., Jones, L. A., and Cohen, A. S. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphan, prednisone, and colchicine versus colchicine only. Am. J. Med., 100: 290-298, 1996.
7. Kyle, R. A., Gertz, M. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Lacy, M. Q., and Therneau, T. M. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N. Engl. J. Med., 336: 1202-1207, 1997.
8. Dhodapkar, M. V., Jagannath, S., Vesole, D., Munshi, N., Naucke, S., Tricot, G., and Barlogie, B. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk. Lymphoma, 27: 351-356, 1997.
9. Palladini, G., Anesi, E., Perfetti, V., Obici, L., Invernizzi, R., Balduini, C., Ascari, E., and Merlini, G. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br. J. Haematol., 113: 1044-1046, 2001.
10. Comenzo, R. L., Vosburgh, E., Falk, R. H., Sanchorawala, V., Reisinger, J., Dubrey, S., Dember, L. M., Berk, J. L., Akpek, G., LaValley, M., O'hara, C., Arkin, C. F., Wright, D. G., and Skinner, M. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood, 91: 3662-3670, 1998.
11. Comenzo, R. L., Sanchorawala, V., Fisher, C., Akpek, G., Farhat, M., Cerda, S., Berk, J. L., Dember, L. M., Falk, R., Finn, K., Skinner, M., and Vosburgh, E. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br. J. Haematol., 104: 553-559, 1999.
12. Comenzo, R. L., and Gertz, M. A. Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 99: 4276-4282, 2002.
13. Hrncic, R., Wall, J., Wolfenbarger, D. A., Murphy, C. L., Schell, M., Weiss, D. T., and Solomon, A. Antibody-mediated resolution of light chain-associated amyloid deposits. Am. J. Pathol., 157: 1239-1246, 2000.
14. Jones, S. T., and Bendig, M. M. Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Biotechnology, 9: 579, 1991.
15. Güssow, D., and Clackson, T. Direct clone characterization from plaques and colonies by the polymerase chain reaction. Nucleic Acids Res., 17: 4000, 1989.
16. Wall, J., Murphy, C. L., and Solomon, A. In vitro immunoglobulin light chain fibrillogenesis. Methods Enzymol., 309: 204-217, 1999.
17. Lundmark, K., Westermark, G. T., Nystrom, S., Murphy, C. L., Solomon, A., and Westermark, P. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc. Natl. Acad. Sci. USA 99: 6979-6984.
18. Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T. M., Dallaire, B. K., Wey, K., Royston, I., Davis, T., and Levy, R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90: 2188-2195, 1997.
19. Pras, M., Schubert, M., Zucker-Franklin, D., Rimon, A., and Franklin, E. C. The characterization of soluble amyloid prepared in water. J. Clin. Investig., 47: 924-933, 1968.
20. Wall, J., Schell, M., Hrncic, R., Macy, S., Wooliver, C., Wolfenbarger, D., Murphy, C., Donnell, R., Weiss, D. T., and Solomon, A. Treatment of amyloidosis using an anti-fibril monoclonal antibody: pre-clinical efficacy in a murine model of AA-amyloidosis. M. Bély and Á. Apáthy (eds.), Amyloid and Amyloidosis, IXth International Symposium on Amyloidosis, pp. 158-160. David Apathy, Budapest, Hungary, 2001.
21. Solomon, A., Weiss, D. T., Macy, S. D., Antonucci, R. A. Immunocytochemical detection of kappa and lambda light chain V region subgroups in human B-cell malignancies. Am. J. Pathol., 137: 855-862, 1990.